Sunnyvale, California — November 24, 2025 — Leads & Copy — BioCardia, Inc. [NASDAQ: BCDA] has appointed Farhan Shahab as its new Vice President of Quality. Shahab brings more than 25 years of experience to the role, joining BioCardia from Welldoc, a digital health company focused on chronic disease management, where he was Vice President of Quality and Regulatory.
Prior to his role at Welldoc, Shahab served as Senior Director of Regulatory Affairs and Quality Assurance at Intuity Medical, a blood glucose monitoring device company. He also held the position of Director of Quality Assurance and Regulatory Compliance at Moximed, an orthopedic device company, and served as Senior Director, Quality Engineering at AngioScore, a catheter manufacturer.
Earlier in his career, Shahab was Manager, Quality Engineering and Quality Systems at Medtronic, where he supported the integration of two major acquisitions.
Shahab holds a Bachelor of Science in Chemical Engineering from the University of Massachusetts and an MBA from the University of Phoenix. He is also a Regulatory Affairs Certified (RAC) professional and a Certified Auditor (Exemplar Global), demonstrating his commitment to quality systems compliance and strategic regulatory alignment.
Peter Altman, PhD, CEO of BioCardia, commented on the appointment, stating that Shahab’s expertise in product quality management and regulatory submissions would be invaluable to the team. Altman expressed his delight in welcoming Shahab, citing his proven leadership and relevant experience as potentially accelerating the company’s ability to commercialize its investigational products.
BioCardia, Inc., headquartered in Sunnyvale, California, is focused on cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. The company’s biotherapeutic platforms include CardiAMP® autologous and CardiALLO™ allogeneic cell therapies, with three clinical-stage product candidates in development. These therapies are supported by BioCardia’s Helix™ biotherapeutic delivery and Morph® vascular navigation product platforms.
Miranda Peto, Investor Relations, can be contacted by email at mpeto@BioCardia.com or by phone at 650-226-0120. Investor inquiries can be directed to David McClung, Chief Financial Officer, by email at investors@BioCardia.com or by phone at 650-226-0120.
Source: BioCardia, Inc.
